Veradermics (MANE) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Veradermics is the larger company by market cap ($5.47 billion vs $4.92 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MANE | TVTX |
|---|---|---|
| Share price | $130.99 | $52.20 |
| Market cap | $5.47B | $4.92B |
| 1-day change | +18.06% | -2.32% |
| YTD return | — | +39.86% |
| 1-year return | — | +109.57% |
| 5-year return | — | +118.12% |
| Forward P/E | — | 9.26 |
| EPS (TTM) | $-4.24 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $490.73M |
| Revenue growth (YoY) | — | +110.45% |
| Net income (latest FY) | $-70.00M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | — | -12.80% |
| Net margin | — | -5.21% |
| 52-week high | $136.72 | $68.73 |
| 52-week low | $32.00 | $22.59 |
| Distance from 52-week high | -4.19% | -24.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +24.82% | +44.08% |
| Average volume | 729.81K | 1.58M |
| Shares outstanding | 41.78M | 94.26M |
| Employees | 37 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
MANE vs TVTX FAQ
Which is bigger, Veradermics or Travere Therapeutics?
Veradermics (MANE) is larger, with a market capitalization of $5.47B compared with $4.92B for Travere Therapeutics (TVTX).
Are Veradermics and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.